<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170704034897N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-01-30</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Efficacy of dried lime in common cold among Hajj pilgrims</public_title>
      <acronym></acronym>
      <scientific_title>Preventive efficacy of dried lime (Citrus aurantifulia) in common cold among Hajj pilgrims: A randomized, double-blind placebo-controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2014-09-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/28781</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: One hundred and twelve eligible patients were randomized into two parallel groups. A statistician generated a randomized list by using NCSS (statistical software) with simple block randomization method. All patients visited by a general practitioner and enrolled participants in the trial were assigned to drug or placebo group, according to randomization list, Blinding description: In this study, the participants, the general practitioner who visited the patients, the data collection authorities, those who evaluate the outcome, and Data Saftey and Monitoring Committee to assign study groups Were blind. But the main investigator was not blind to the study groups.
Also, the author of the article had been blind at the end of the work too.</study_design>
      <phase>N/A</phase>
      <hc_freetext>common cold.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in drug group received dried lime capsules, 500 mg in a single dose per day for four weak. Test drug consisting of Citrus aurantifulia and sugar. The dried fruit of Citrus aurantifulia was purchased from the green market in Shiraz (Iran) and was authenticated by a botanist and was kept at the Herbarium of the Faculty of Pharmacy, Shiraz University of Medicinal Sciences, Shiraz, Iran. 500 milligram of the milled powder of dried fruit of Citrus aurantifulia and 50 milligrams of sugar as filler filled into a capsule. Intervention 2: Control group: In the placebo group, patients received placebo capsules with the same method.(a single dose per day for four weak) Placebo capsule, consisting of 550 milligrams of flour with identical size and shape to test drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the individual information of the participants, such as information on the main outcome of the data in the study, is the possibility of sharing. This information includes some of the demographic characteristics and data related to the severity of a cough, rhinorrhea, body pain and fever.

When:
Start the access period 6 months after publishing the results for 1 month

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
Only a descriptive survey of data is allowed.

Where to obtain:
By sending an email to the scientific responsible of the study, Dr. Pasalar, at the following address:
pasalar@sums.ac.ir

How to obtain:
After the request has been sent, it will be answered within a maximum of 2 months.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Seyed Hossein Owji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz Medical School, Imam Hossein Square, Shiraz, Iran</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 71 3212 2970</telephone>
        <email>owji_h@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mehdi Pasalar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz Medical School, Imam Hossein Square, Shiraz, Iran</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134845794</zip>
        <telephone>+98 71 3233 8476</telephone>
        <email>pasalar@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All men and women aged 35 to 80 years
participating in the Hajj
who agree with the aim of the study</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>participants who have asthma
participants who have a chronic obstructive pulmonary disease
participants who have uncontrolled heart diseases
participants who have heart failure
participants who have a hepatic and renal failure
participants who have a history of previous chest surgery.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J00</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acute nasopharyngitis [common cold]</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in drug group received dried lime capsules, 500 mg in a single dose per day for four weak. Test drug consisting of Citrus aurantifulia and sugar. The dried fruit of Citrus aurantifulia was purchased from the green market in Shiraz (Iran) and was authenticated by a botanist and was kept at the Herbarium of the Faculty of Pharmacy, Shiraz University of Medicinal Sciences, Shiraz, Iran. 500 milligram of the milled powder of dried fruit of Citrus aurantifulia and 50 milligrams of sugar as filler filled into a capsule.</i_keyword>
      <i_keyword>Control group: In the placebo group, patients received placebo capsules with the same method.(a single dose per day for four weak) Placebo capsule, consisting of 550 milligrams of flour with identical size and shape to test drug.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The severity of a cough. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).</prim_outcome>
      <prim_outcome>The severity of rhinorrhea. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).</prim_outcome>
      <prim_outcome>The severity of fever. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).</prim_outcome>
      <prim_outcome>The severity of body pain. Timepoint: First , second, third and fourth week after intervention. Method of measurement: By self-administered questionnaire that ranged from 0-5 scores (without symptoms to severe symptoms).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-05-01</approval_date>
        <contact_name>Ethics committee of Shiraz University of medical sciences</contact_name>
        <contact_address>Shiraz University of medical sciences, Zand street, Shiraz Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
